Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
07/27/2022* -- Results Q1 2023 -- 0.62 --
07/27/2022* 08:00 EST Earnings Call Q1 2023 -- -- --
01/28/2022 -- Results Q3 2022 0.57 0.86 -33.63%
01/28/2022 08:00 EST Earnings Call Q3 2022 -- -- --
10/29/2021 -- Results Q2 2022 0.80 0.64 24.62%
10/29/2021 08:00 EST Earnings Call Q2 2022 -- -- --
07/27/2021 -- Results Q1 2022 0.46 0.67 -31.11%
07/27/2021 08:00 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 01/28/2022
Beat/Miss Upgrade
Return Since -1.64%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Headquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.
URL https://www.drreddys.com
Investor Relations URL http://www.drreddys.com/investors.aspx
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Large Cap/Growth
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Jan. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jul. 08, 2021

Dividends

Dividend Per Share (TTM) 0.3372
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.4614
Yield to Sector 0.3182
Yield to Industry 0.272
Last Dividend Amt. 0.3365
Dividend Frequency Annually
Last Ex-Dividend Date Jul. 08, 2021
Yield (TTM) 0.61%
Forward Yield 0.61%
Payout Ratio 17.55%
Cash Payout Ratio 45.77%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-7.75%
-1.64%
-16.42%
1.25%
7.64%
76.80%
-7.83%
-15.87%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
17.27%
-64.52%
-36.84%
75.00%
-17.99%
-57.55%
86.02%
-22.30%
--
--
24.37%
38.45%
2.00%
3.01%
-39.64%
-68.42%
--
--
--
--
--
-19.32%
-59.34%
-83.91%
-4.67%
-12.13%
19.40%
5.88%
14.34%
3.41%
-3.82%
6.47%
As of May 20, 2022.

Profile

Edit
Headquartered in India, Dr. Reddy’s Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company’s sales are well dispersed across North America, India, and other emerging markets.
URL https://www.drreddys.com
Investor Relations URL http://www.drreddys.com/investors.aspx
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Large Cap/Growth
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Jan. 28, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Jul. 08, 2021

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F00001DCL3 349.00 USD 3.49%
RBF1416 207.34M USD 3.06%
F000015O2B 301.00 USD 3.01%
FNI 1.856M USD 2.45%
BICK 389730.0 USD 2.36%
ZLE.TO 1.316M USD 1.35%
PBEE 71481.00 USD 0.51%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RDY Tweets